BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 8761369)

  • 1. TP53 mutation analyses on breast carcinomas: a study of paraffin-embedded archival material.
    Gretarsdottir S; Tryggvadottir L; Jonasson JG; Sigurdsson H; Olafsdottir K; Agnarsson BA; Ogmundsdottir H; Eyfjörd JE
    Br J Cancer; 1996 Aug; 74(4):555-61. PubMed ID: 8761369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of TP53 alterations in breast carcinoma.
    Andersen TI; Holm R; Nesland JM; Heimdal KR; Ottestad L; Børresen AL
    Br J Cancer; 1993 Sep; 68(3):540-8. PubMed ID: 8102535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 mutations and histological type of invasive breast carcinoma.
    Marchetti A; Buttitta F; Pellegrini S; Campani D; Diella F; Cecchetti D; Callahan R; Bistocchi M
    Cancer Res; 1993 Oct; 53(19):4665-9. PubMed ID: 8402644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TP53 alterations in atypical ductal hyperplasia and ductal carcinoma in situ of the breast.
    Chitemerere M; Andersen TI; Holm R; Karlsen F; Børresen AL; Nesland JM
    Breast Cancer Res Treat; 1996; 41(2):103-9. PubMed ID: 8944328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TP53 mutations and abnormal p53 protein staining in breast carcinomas related to prognosis.
    Thorlacius S; Thorgilsson B; Björnsson J; Tryggvadottir L; Börresen AL; Ogmundsdottir HM; Eyfjörd JE
    Eur J Cancer; 1995 Oct; 31A(11):1856-61. PubMed ID: 8541113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value.
    Kovach JS; Hartmann A; Blaszyk H; Cunningham J; Schaid D; Sommer SS
    Proc Natl Acad Sci U S A; 1996 Feb; 93(3):1093-6. PubMed ID: 8577720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic alterations of the TP53 gene, p53 protein expression and HPV infection in primary cervical carcinomas.
    Helland A; Holm R; Kristensen G; Kaern J; Karlsen F; Trope C; Nesland JM; Børresen AL
    J Pathol; 1993 Oct; 171(2):105-14. PubMed ID: 8283348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of TP53 mutations determined by next-generation "deep" sequencing in prognosis of estrogen receptor-positive breast cancer.
    Uji K; Naoi Y; Kagara N; Shimoda M; Shimomura A; Maruyama N; Shimazu K; Kim SJ; Noguchi S
    Cancer Lett; 2014 Jan; 342(1):19-26. PubMed ID: 23973262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-risk human papilloma virus infection, tumor pathophenotypes, and BRCA1/2 and TP53 status in juvenile breast cancer.
    Aceto GM; Solano AR; Neuman MI; Veschi S; Morgano A; Malatesta S; Chacon RD; Pupareli C; Lombardi M; Battista P; Marchetti A; Mariani-Costantini R; Podestà EJ
    Breast Cancer Res Treat; 2010 Aug; 122(3):671-83. PubMed ID: 19851859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TP53 mutation is an independent prognostic marker for poor outcome in both node-negative and node-positive breast cancer.
    Overgaard J; Yilmaz M; Guldberg P; Hansen LL; Alsner J
    Acta Oncol; 2000; 39(3):327-33. PubMed ID: 10987229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nuclear accumulation of p53 protein correlates with mutations in the p53 gene on archival paraffin-embedded tissues of human breast cancer.
    Umekita Y; Kobayashi K; Saheki T; Yoshida H
    Jpn J Cancer Res; 1994 Aug; 85(8):825-30. PubMed ID: 7928628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: high frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis.
    Abdel-Fattah R; Challen C; Griffiths TR; Robinson MC; Neal DE; Lunec J
    Br J Cancer; 1998 Jun; 77(12):2230-8. PubMed ID: 9649138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship of DNA ploidy to hormone receptor status and proliferation in invasive breast carcinoma.
    Spiethoff A; Schenck A; Bohrer M
    J Cancer Res Clin Oncol; 2000 Dec; 126(12):707-10. PubMed ID: 11153143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical relevance of immunohistochemical expression of p53-targeted gene products mdm-2, p21 and bcl-2 in breast carcinoma.
    Bánkfalvi A; Tory K; Kemper M; Breukelmann D; Cubick C; Poremba C; Füzesi L; Lellè RJ; Böcker W
    Pathol Res Pract; 2000; 196(7):489-501. PubMed ID: 10926327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers.
    Thor AD; Moore DH II; Edgerton SM; Kawasaki ES; Reihsaus E; Lynch HT; Marcus JN; Schwartz L; Chen LC; Mayall BH
    J Natl Cancer Inst; 1992 Jun; 84(11):845-55. PubMed ID: 1317462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRCA1-related breast cancer in Austrian breast and ovarian cancer families: specific BRCA1 mutations and pathological characteristics.
    Wagner TM; Möslinger RA; Muhr D; Langbauer G; Hirtenlehner K; Concin H; Doeller W; Haid A; Lang AH; Mayer P; Ropp E; Kubista E; Amirimani B; Helbich T; Becherer A; Scheiner O; Breiteneder H; Borg A; Devilee P; Oefner P; Zielinski C
    Int J Cancer; 1998 Jul; 77(3):354-60. PubMed ID: 9663595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on p53 immunolocalisation in breast cancer and its prognostic significance.
    Meenakshi A; Manoharan V
    Hum Antibodies; 1999; 9(3):171-6. PubMed ID: 10690631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
    Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
    Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of mutation type on prognostic and predictive values of TP53 status in primary breast cancer patients.
    Dobes P; Podhorec J; Coufal O; Jureckova A; Petrakova K; Vojtesek B; Hrstka R
    Oncol Rep; 2014 Oct; 32(4):1695-702. PubMed ID: 25051299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutational analysis of the PRL receptor gene in human breast tumors with differential PRL receptor protein expression.
    Glasow A; Horn LC; Taymans SE; Stratakis CA; Kelly PA; Kohler U; Gillespie J; Vonderhaar BK; Bornstein SR
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3826-32. PubMed ID: 11502819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.